我国药物警戒制度实施与ICH药物警戒指导原则转化适用

doi:10.19803/j.1672-8629.2020.02.01

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (2): 65-71.
DOI: 10.19803/j.1672-8629.2020.02.01

我国药物警戒制度实施与ICH药物警戒指导原则转化适用

杨悦^1,2

1沈阳药科大学药品监管科学研究院,辽宁沈阳 110016;
2沈阳药科大学国际食品药品政策与法律研究中心,辽宁沈阳 110016

收稿日期:2019-12-14 修回日期:2020-06-22 出版日期:2020-02-15 发布日期:2020-02-26
作者简介:杨悦,女,博士,教授,博导,药事管理与药物警戒研究。

Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline

YANG Yue^1,2

1Research Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Shenyang Liaoning 110016, China;
2International Center for Food and Drug Policy and Law, Shenyang Pharmaceutical University, Shenyang Liaoning 110016, China

Received:2019-12-14 Revised:2020-06-22 Online:2020-02-15 Published:2020-02-26

摘要/Abstract

摘要： 本文将原《药品管理法》中药品不良反应报告和监测制度与新修订《药品管理法》中的药物警戒制度要求差异进行分析,从药物警戒涵义入手,结合我国药品审评审批改革以来新药上市加速的宏观背景,指出药物警戒制度应当作为新药上市审评进入“高速路”的制动机制。与ICH E2系列指导原则转化应用相结合,对落实新修订《药品管理法》中药物警戒要求提出转变监测和报告理念,提高信号检测效率和能力,开展累积性风险获益评价,探索适合中国国情的风险管理计划要求等具体建议和思路。

关键词: 药品管理法, 药物警戒, ICH E2, 不良事件, 风险管理计划

Abstract: This paper is intended to analyze the difference in adverse reaction reporting and monitoring systems between the previous Drug Administration Law and the pharmacovigilance system specified in the newly revised Drug Administration Law. Starting with the meaning of pharmacovigilance and combined with the macro background of acceleration of new drug authorization since the reform of drug review and approval in China, this paper points out that the pharmacovigilance system can be compared to the braking mechanism for new drug review to enter the “expressway”. Combined with the transformation and application of ICH E2 series guidelines, this paper makes recommendations for the implementation of pharmacovigilance requirements according to the revised Drug Administration Law, such as changing notions about the monitoring and reporting of drugs, improving the efficiency and ability of signal detection, carrying out cumulative risk benefit evaluation, and exploring the requirements of risk management plans suited to China.

Key words: Drug Administration Law, pharmacovigilance, ICH E2, adverse event, risk management plan

中图分类号:

R951

杨悦. 我国药物警戒制度实施与ICH药物警戒指导原则转化适用[J]. 中国药物警戒, 2020, 17(2): 65-71.

YANG Yue. Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 65-71.

参考文献

[1] WHO.Report of a WHO Meeting.International Drugmonitoring: The Role of Nationalcentres[EB/OL].[2019-10-10].https://www.who-umc.org/media/2680/who-technical-report-498.pdf,1972.
[2] Patrick Waller.An Introduction to Pharmacovigilance[M]. Southampton UK:A John Wiley & Sous,Ltd.,Publication,2010:1.
[3] Begaud B,Glossary. Methodological approaches in pharmacoepidemiology[M]. Amsterdam: Elsevier Science Publishers B.V.,1993:157-171.
[4] 彭丽丽,王丹,沈璐,等.药物警戒的起源与发展[J].中国药物警戒,2016,13(7):410-413.
[5] 黄传海. 基层药品不良反应监测组织架构及可持续发展研究[D].山东大学,2007:34.
[6] 祝眉娜. 我国药物警戒体系建设的研究[D].沈阳药科大学, 2008:16.
[7] Nicholas S.Downing, Nilay D.Shah, Jenerius A.Aminawung, et al. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010[J]. JAMA The Journal of the American Medical Association, 2017, 317(18):1854-1863.
[8] ICH.Clinical Safety Data Safety Data Management: Definitions and Standards for Expedited ReportingA(E2A) S[EB/OL].(1995-05-01) [2019-10-10].https://database.ich.org/sites/default/files/E2A_Guideline.pdf.
[9] ICH.Post-Approval Pproval Safety Data Management: Definitions and Standards for Expedited Reporting(E2D) [EB/OL].[2019-10-10].https://database.ich.org/sites/default/files/E2D_Guideline.pdf.
[10] FDA.Sec. 314.80 Postmarketing reporting of adverse drug experiences,[EB/OL].(2003-11)[2019-10-10].https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.80:
[11] 李姗,杨悦.WHO推荐的药物警戒方法:监测药品不良反应信号[J].中国药物评价,2012,29(04):267-269.
[12] 侯永芳,刘翠丽,宋海波,等.药品不良反应信号检测模型优化及应用[J].中国药物警戒,2016,13(7):408-409,421.
[13] FDA CDER &CBER. Guidance for Industry:Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment[M/OL].(2005-03) [2019-10-10].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmaco-vigilance-practices-and-pharmacoepidemiologic-assessment.
[14] Uppsala Monitoring Centre.Better Signal Detection With Vigirank[EB/OL].( 2018-04-18) [2019-10-11].https://www.who-umc.org/media/164251/uppsalareports78web.pdf.
[15] 王琳琳,杨悦,王淑玲.美国FDA哨点系统的应用及启示[J].中国药物警戒,2019,16(2):81-87.
[16] ICH.Periodic Benefit-Risk Evaluation Report(Current Step 4 version)[EB/OL]. (2012-11-15)[2019-10-10].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2C_R2_Step4.pdf.
[17] 袁丽,杨悦.ICH E2C(R2)定期风险-效益评估报告指导原则简介及启示[J].中国药物警戒,2013,10(11):650-654.
[18] Pharmacovigilance Planning.ICH E2E)[EB/OL]. (2004-11-18)[2019-10-18]. http:// www.ich.org/cache/compo/475-272-1.html # E2E.

我国药物警戒制度实施与ICH药物警戒指导原则转化适用

Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194.
[2]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[3]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[4]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[5]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[6]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[7]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[8]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.
[9]	何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.
[10]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[11]	赵稳华, 舒鹤, 倪晨明, 郭晋敏. 基于FAERS数据库的氨吡啶缓释片不良反应信号挖掘分析[J]. 中国药物警戒, 2023, 20(6): 684-690.
[12]	陈亚昆, 门鹏, 王攀. 基于FAERS数据库的4种磷酸二酯酶5抑制剂安全性分析[J]. 中国药物警戒, 2023, 20(6): 691-696.
[13]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[14]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[15]	资文瑞, 杨秋月, 苏俊, 谢江安. 我国上市人乳头瘤病毒疫苗接种及安全性研究[J]. 中国药物警戒, 2023, 20(3): 311-316.